CTTHWGFTLC, CYCLIC (TFA)

CTTHWGFTLC, CYCLIC (TFA)

• UNSPSC Description: CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC50 value for MMP-9 is ~8 μM[1].
• Target Antigen: MMP
• Type: Peptides
• Related Pathways: Metabolic Enzyme/Protease
• Applications: COVID-19-immunoregulation
• Field of Research: Cancer; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/ctthwgftlc-cyclic-tfa.html
• Purity: 98.91
• Solubility: DMSO : ≥ 50 mg/mL
• Smiles: O=C(N[C@H]1CC2=CNC3=CC=CC=C23)[C@H](CC4=CN=CN4)NC([C@]([H])([C@@H](C)O)NC([C@]([H])([C@@H](C)O)NC([C@@H](N)CSSC[C@@H](C(O)=O)NC([C@H](CC(C)C)NC([C@]([H])([C@@H](C)O)NC([C@H](CC5=CC=CC=C5)NC(CNC1=O)=O)=O)=O)=O)=O)=O)=O.O=C(C(F)(F)F)O
• Molecular Weight: 1280.35
• References & Citations: [1]Medina OP, et al. Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res. 2001 May 15;61(10):3978-85.
• Shipping Conditions: Blue Ice
• Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
• Clinical Information: No Development Reported